1.van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW: Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. Journal of the American College of Cardiology 2011, 58(21):2241–2247.
2.Larsen SH, Emmertsen K, Hjortdal VE, Nielsen-Kudsk JE: Adverse events in transcatheter interventions for congenital heart disease: a population-based long-term study. Congenital heart disease 2015, 10(2):153–158.
3.Ng SM, Jin X, Yates R, Kelsall AW: Outcome of noncardiac surgery in children with congenital heart disease performed outside a cardiac center. Journal of pediatric surgery 2016, 51(2):252–256.
4.Faraoni D, Zurakowski D, Vo D, Goobie SM, Yuki K, Brown ML, DiNardo JA: Post-Operative Outcomes in Children With and Without Congenital Heart Disease Undergoing Noncardiac Surgery. Journal of the American College of Cardiology 2016, 67(7):793–801.
5.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA et al: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016, 37(27):2129–2200.
6.Hsu JH, Keller RL, Chikovani O, Cheng H, Hollander SA, Karl TR, Azakie A, Adatia I, Oishi P, Fineman JR: B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J Thorac Cardiov Sur 2007, 134(4):939–945.
7.Niedner MF, Foley JL, Riffenburgh RH, Bichell DP, Peterson BM, Rodarte A: B-type natriuretic peptide: perioperative patterns in congenital heart disease. Congenit Heart Dis 2010, 5(3):243–255.
8.Nahum E, Pollak U, Dagan O, Amir G, Frenkel G, Birk E: Predictive Value of B-type Natriuretic Peptide Level on the Postoperative Course of Infants with Congenital Heart Disease. Isr Med Assoc J 2013, 15(5):216–220.
9.Cantinotti M, Giordano R, Scalese M, Molinaro S, della Pina F, Storti S, Arcieri L, Murzi B, Marotta M, Pak V et al: Prognostic role of BNP in children undergoing surgery for congenital heart disease: analysis of prediction models incorporating standard risk factors. Clin Chem Lab Med 2015, 53(11):1839–1846.
10.Mir TS, Haun C, Lilje C, Laer S, Weil J: Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatric Cardiology 2006, 27(2):209–216.
11.Walsh R, Boyer C, LaCorte J, Parnell V, Sison C, Chowdhury D, Ojamaa K: N-terminal B-type natriuretic peptide levels in pediatric patients with congestive heart failure undergoing cardiac surgery. J Thorac Cardiovasc Surg 2008, 135(1):98–105.
12.Goei D, van Kuijk JP, Flu WJ, Hoeks SE, Chonchol M, Verhagen HJM, Bax JJ, Poldermans D: Usefulness of Repeated N-Terminal Pro-B-Type Natriuretic Peptide Measurements as Incremental Predictor for Long-Term Cardiovascular Outcome After Vascular Surgery. American Journal of Cardiology 2011, 107(4):609–614.
13.Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong JJ, Shi VC et al: Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology 2016, 68(22):2425–2436.
14.Qu JB, Liang HY, Zhou N, Li LJ, Wang YF, Li JB, Cui YQ: Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery. J Thorac Cardiov Sur 2017, 154(2):631–640.
15.Sandhu S, Har BJ, Aggarwal SG, Kavanagh KM, Ramadan D, Exner DV, Investigators R: Predictive Value of Repeated Versus Single N-Terminal Pro B-Type Natriuretic Peptide Measurements Early After-Myocardial Infarction. Pace 2009, 32:S86-S89.
16.Donohue MC, Aisen PS: Mixed model of repeated measures versus slope models in Alzheimer’s disease clinical trials. The journal of nutrition, health & aging 2012, 16(4):360–364.
17.Andersen SW, Millen BA: On the practical application of mixed effects models for repeated measures to clinical trial data. Pharmaceutical statistics 2013, 12(1):7–16.
18.Maurissen JP, Vidmar TJ: Repeated-measure analyses: Which one? A survey of statistical models and recommendations for reporting. Neurotoxicol Teratol 2017, 59:78–84.
19.Roberts MA, Hare DL, Sikaris K, Ierino FL: Temporal trajectory of B-type natriuretic peptide in patients with CKD stages 3 and 4, dialysis, and kidney transplant. Clinical journal of the American Society of Nephrology: CJASN 2014, 9(6):1024–1032.
20.Beltrami M, Ruocco G, Ibrahim A, Lucani B, Franci B, Nuti R, Palazzuoli A: Different trajectories and significance of B-type natriuretic peptide, congestion and acute kidney injury in patients with heart failure. Internal and emergency medicine 2017.
21.Greene SJ, Maggioni AP, Fonarow GC, Solomon SD, Bohm M, Kandra A, Prescott MF, Reimund B, Hua TA, Lesogor A et al: Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. European journal of heart failure 2015, 17(1):98–108.
22.Qu J, Liang H, Zhou N, Li L, Wang Y, Li J, Cui Y: Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery. The Journal of thoracic and cardiovascular surgery 2017.
23.Salis S, Mazzanti VV, Merli G, Salvi L, Tedesco CC, Veglia F, Sisillo E: Cardiopulmonary Bypass Duration Is an Independent Predictor of Morbidity and Mortality After Cardiac Surgery. J Cardiothor Vasc An 2008, 22(6):814–822.
24.Al-Sarraf N, Thalib L, Hughes A, Houlihan M, Tolan M, Young V, McGovern E: Cross-clamp time is an independent predictor of mortality and morbidity in low- and high-risk cardiac patients. Int J Surg 2011, 9(1):104–109.
25.Nissinen J, Biancari F, Wistbacka JO, Peltola T, Loponen P, Tarkiainen P, Virkkila M, Tarkka M: Safe time limits of aortic cross-clamping and cardiopulmonary bypass in adult cardiac surgery. Perfusion-Uk 2009, 24(5):297–305.
26.Larsen SH, Pedersen J, Jacobsen J, Johnsen SP, Hansen OK, Hjortdal V: The RACHS–1 risk categories reflect mortality and length of stay in a Danish population of children operated for congenital heart disease. Eur J Cardio-Thorac 2005, 28(6):877–881.
27.Cuypers JAAE, Eindhoven JA, Slager MA, Opic P, Utens EMWJ, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT et al: The natural and unnatural history of the Mustard procedure: long-term outcome up to 40 years. European Heart Journal 2014, 35(25):1666-+.